readthroughSign in
CompanyIMRXNasdaqCambridge, MA

Immuneering Corporation

Immuneering develops Deep Cyclic Inhibitors for oncology, including atebimetinib, a MEK inhibitor in late-stage clinical development for RAS/RAF/MAPK-driven cancers.

8-KNov 9Latest SEC filing
Nov 9Latest story